Journal
JOURNAL OF CROHNS & COLITIS
Volume 9, Issue 4, Pages 356-366Publisher
OXFORD UNIV PRESS
DOI: 10.1093/ecco-jcc/jjv033
Keywords
Vedolizumab; inflammatory bowel disease; Crohn's disease; ulcerative colitis
Categories
Funding
- AbbVie
- Asahi-Kasei
- Bristol-Myers Squibb
- Coronado Biosciences
- Cosmo Technologies Ltd.
- Ferring Pharmaceuticals
- Genentech
- Genzyme Corp.
- GlaxoSmithKline
- Janssen
- Lexicon Pharmaceuticals
- Merck Research Laboratories
- Millennium Pharmaceuticals
- Nisshin Kyorin Pharmaceutical Co., Ltd.
- Novartis
- Novo Nordisk A/S
- NPS Pharmaceuticals
- PDL BioPharma
- Pfizer
- Procter and Gamble
- Proximagen
- Santarus, Inc. of Salix Pharmaceuticals, Inc.
- Schering Plough
- Shire
- Sigmoid Pharma Ltd.
- Tillotts Pharma AG
- Topivert
- TxCell SA
- UCB
- Warner Chilcott UK Ltd.
Ask authors/readers for more resources
Vedolizumab (VDZ), a humanized monoclonal antibody that selectively targets a4 beta 7 integrin, is approved for use in inflammatory bowel disease (IBD). Here we review the evidence for the safety and efficacy of VDZ in IBD, in order to identify patients likely to benefit from therapy and to integrate VDZ into clinical practice. A bibliographic search was performed of the online databases MEDLINE, EMBASE, PubMed, and the Cochrane Library, using the key words 'inflammatory bowel diseases' OR 'ulcerative colitis' OR 'Crohn's disease' AND 'vedolizumab' OR 'MLN0002' OR 'integrin alpha4beta7' OR 'anti-integrin'. Eight-nine articles were returned using the primary search. Eight randomized controlled trials, one Cochrane review, and two network meta-analyses were identified. VDZ is well tolerated with a low rate of adverse events (similar to placebo), and is associated with minimal systemic immunosuppression. VDZ is effective for induction and maintenance of remission in outpatients with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD) who have failed conventional and anti-tumor necrosis factor (anti-TNF) therapy. VDZ is also a first-line alternative to anti-TNF therapy in UC. The efficacy of VDZ is best assessed at, or beyond, 10 weeks of therapy. The safety, tolerability, and efficacy profile of VDZ place it as a new therapy in IBD, though further trials directly comparing VDZ with other biological agents as well as pragmatic studies to evaluate cost-effectiveness are necessary.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available